Gastroenterology

The treatment was well-tolerated, with all serious treatment emergent adverse events considered not related to the treatment.

The results show the ADR in the early session of the unassisted group was significantly higher compared to those in the late session.

Sofosbuvir-based regimens were the most commonly prescribed therapies to treat hepatitis C virus in Asia, Africa, and the Commonwealth of Independent States.

The results show adherence to 6 quality indicators was linked to improvements in the post-intervention cohort with significant increases in C difficile testing, CRP testing, testing for latent tuberculosis, thromboprophylaxis, adequate corticosteroids prescription, and limitation of narcotics prescribed.

The results also show a decrease in antibiotic use, hospital length of stay, and overall cost to the patient.

Thus far, the phase 2 data on CP101 was generally positive for the treatment of recurrent C difficile infections.

While 20% of the patient population had a Fib-4 index greater than 1.3, including 1 case of a Fib-4 index greater than 2.67, the investigators did not identify a significant increase in Fib-4 index in patients with fatty liver compared to those who did not develop fatty liver.

The rate of adverse events was lower in the combination group than it was in patients in the guselkumab or golimumab monotherapy groups at week 50.

The majority of healthcare workers included in the study were immune to both measles and rubella.

The FDA has approved several biologics in recent years for the treatment of patients with inflammatory bowel disease.

There is very little data on long-term outcomes from pediatric patients with inflammatory bowel disease treated with anti-TNF biosimilars.

An analysis of the UK Biobank suggests individuals with celiac disease had an incidence rate of 9.0 CVD cases per 1000 person years compared with 7.4 per 1000 person years in people with no celiac disease.

Risankizumab is the latest biologic approved by the FDA and the first-ever IL-23A targeted therapy approved for the treatment of patients with Crohn's disease.

There is not much data available on the interaction between Paxlovid and tacrolimus.

Dose de-escalation of tofacitinib resulted in less hospitalizations for patients with ulcerative colitis.

The potential for personalized medicine in inflammatory bowel disease might. be realized in the next few years.

Upadacitinib was not approved by the FDA until 2022 for patients with ulcerative colitis.

The 12-24 session counseling program also resulted in improvements in sleep quality, fatigue level, and stress levels for patients with inflammatory bowel disease.

The majority of patients who achieved persistence at the 12 month mark were also corticosteroid free.

The product is a combination of herbal compounds curcumin and QingDai called CurQD.

Microscopic inflammation can be an important indicator of disease activity in patients with ulcerative colitis.

The prevalence of advanced colorectal neoplasms was higher in men and older individuals.

There was no differences in serious adverse event rates between patients treated with the combination therapy and patients who withdrew from infliximab or immunosuppressant therapy.

The guidelines include advocating for more preventative care and changing how the disease is diagnosed.

Dupilumab is currently the only treatment for eosinophilic esophagitis approved by the US Food and Drug Administration.